5 Trending Pharma Articles to Start Off the Month
Just as the groundhog has been thought to have predictive abilities, identifying the end of winter and start of spring, today’s technology has found a way to provide us with crucial business answers that we would have never been able to discover before. Technology has presented tools that can bridge the gap between health care providers, patients, and Pharma companies. This week’s trending Pharma articles reveal insights on patient centricity, closed-loop marketing (CLM), advanced analytics, Pharma BI solutions, and some major predictions for technology in Pharma for 2015.
1. Patient Centricity Could be the Biggest Opportunity in Multiple Sclerosis
Written by Suzanne Elvidge, published on EyeForPharma
Multiple Sclerosis (MS) is an autoimmune, inflammatory disease of the central nervous system (CNS) that affects approximately 400,000 people in the United States.1 A diagnosis of MS often seems like a death sentence as it is known to progressively evolve into disability. In this article, Suzanne Elvidge discusses how patient centricity can create the biggest opportunity in supporting disease management in MS patients. The idea behind patient centricity is making the patient the “point of focus” in drug and product development. If the pharmaceutical industry can create an avenue for patients to access good quality, evidence-based information and support, it would empower patients to make good choices regarding their treatment and help them cope better. In this article, Elvidge puts the spotlight on Tim Kneen, President of Merck Serono (Europe and Canada). Merck Serono has created a product that utilizes a patient-centric approach to empower MS patients. Read the article for more about patient centricity and Merck Serono’s approach.
2. Uncovering the Hidden Value in CLM
Written by Jacky Law, published on PharmaPhorum
Closed-Loop Marketing (CLM) is a technology that was created to harness unique insights about health care practitioners in order to learn their interests, attitudes, and motivations and translate these characteristics into profitability for the Pharma industry. However, the full rewards of CLM are yet to be unveiled. Two big problems discussed in the article are the failure of companies to use CLM technology as more than just a tool to accumulate “tracking” data, and the incorrect use of CLM technology by Pharma reps. Read the article to learn more about what Pharma companies can do to bridge the gap between knowing what health care practitioners want and providing just that.
3. How to Drive Commercial Excellence through Analytics: Lessons from Two Leading Pharmacos
Written by Iain Fratter & Stephen Redden, published on PharmaPhorum
For years, the Pharma industry has harnessed unique opportunities by utilizing data from advanced analytics. Advanced analytics has allowed Pharma companies to make better decisions about how to connect with their customers. This article uses case studies from two big pharmaceutical companies – Novartis and Roche Diagnostics – to showcase how Pharma leaders use advanced analytics to increase sales and market share. The authors summarize three essential lessons on advanced analytics that Pharma companies can learn from these two giants. Read the article to learn more.
4. The Groundhog Weather Predictions; A Tale of Pharma BI Solutions
Written by Annie Reiss, published on Verix Blog
Beginning with the premise from traditional folklore that groundhogs have special predictive abilities, this article chronicles the difference between a Pharma dedicated end-to-end solution and a general front-end solution. In summary, Pharma end-to-end solutions showcase better predictive abilities because they involve a rigorous process of preparing a platform of tools and algorithms that make it possible to analyze all data (leading to actionable insights). On the other hand, front-end solutions are merely based on creating data visualization and dashboard reporting. Reiss emphasizes that BI end-to-end solutions are more powerful than front-end solutions because they combine both sides of “the stage”: front and back. Read this article to learn more about Pharma BI solutions and their importance in Big Data analysis.
5. The Good, the Bad, and the Ugly: CPhI Panel’s Pharma Predictions for 2015
Written by PharmExec Staff, published on PharmExec
This article chronicles compilations of CPhl’s expert panel concerning Pharma predictions for 2015. The PharmExec staff did a wonderful job in dividing these predictions into “the good, bad, and the ugly truths.” A little insight into the “good” predictions: progressive developments in the FDA’s role from “investigator” to “enabler” of better quality processes in Pharma; breakthrough treatments in infectious diseases; and growth in new chemical entities (NCEs) and biopharmaceuticals. Read the article to unravel the full forecast by the CPhl’s expert panel.
1. Tullman, Mark J. “Overview of the epidemiology, diagnosis, and disease progression associated with multiple sclerosis.” Am J Manag Care 19.2 Suppl (2013): S15-20.